This is a LLY news story, published by Yahoo Finance, that relates primarily to Donanemab news.
For more LLY news, you can click here:
more LLY newsFor more Donanemab news, you can click here:
more Donanemab newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Eli Lilly stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest healthcare stock news, growth prospects news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
promising productsThe Motley Fool
•75% Informative
Eli Lilly ( NYSE : LLY ) is trading at more than 120 times earnings.
There's no doubt that it's expensive and that investors are paying a premium for it.
But here's why you may want to buy it anyway.
Donanemab is the company's early Alzheimer's treatment which is still waiting for approval.
At its peak, it could easily be a blockbuster drug which could generate around $5 billion in revenue.
VR Score
66
Informative language
60
Neutral language
41
Article tone
informal
Language
English
Language complexity
39
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
7
Source diversity
2
Affiliate links
no affiliate links